BioCardia, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 52 of BioCardia, Inc.'s SEC filings and found 7 warrant series, 1 ATM program, 4 shelf registrations, 2 S-1 registrations and 2 completed offerings on file for BCDA. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 7, 2026.
Signal8 Summary
BCDA
Cash exhausted, Nasdaq delisting risk
Snapshot
BioCardia is a clinical-stage biotech with no revenue and a history of significant losses. The company lost $8.2 million in FY 2025 and burned $7.4 million in operating cash flow, leaving it with just $2.5 million in cash against a $13.5 million market cap. This cash position was effectively exhausted by the time of the latest report, creating a negative cash runway. The share count has more than doubled over the last year, rising 143% to 6.7 million shares, which is a classic sign of dilution used to fund operations.
What's Happening Right Now
- : BioCardia announced a $4.4 million equity raise on June 8, 2026, which management says extends the cash runway into the first quarter of 2027.
- : The FDA confirmed on June 5, 2026, that data from the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval for the cell therapy system.
- : Japan's PMDA issued a Consultation Record on May 28, 2026, supporting the regulatory submission for CardiAMP, with a planned approval submission in Q4 2026.
- : Positive trial results presented at EuroPCR on May 21, 2026, showed durable improvements in exercise tolerance and reduced angina episodes for patients.
- : Q1 2026 results on May 15, 2026, revealed a net loss of $2.26 million and cash reserves of only $951,000, triggering a Nasdaq delisting notice for failing equity requirements.
